ScholarIQanswers from OpenAlex
Fred Hutch Cancer Center
InstitutionResearch output, impact & collaborations
Fred Hutch Cancer Center is a institution indexed in ScholarIQ from OpenAlex.
What is known about Fred Hutch Cancer Center?
ScholarIQrecord summary
Fred Hutch Cancer Center is a research organisation in Seattle, US. OpenAlex records 57,528 works and 11,331,394 citations for it. 8,260 researchers list it as their most recent affiliation.
How many works does Fred Hutch Cancer Center have?
ScholarIQindexed works
Fred Hutch Cancer Center has 57,528 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Fred Hutch Cancer Center have?
ScholarIQcitation count
Fred Hutch Cancer Center has 11,331,394 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at Fred Hutch Cancer Center?
ScholarIQresearcher count
Fred Hutch Cancer Center has 8,260 researchers in the ScholarIQ index.
What is the average h-index at Fred Hutch Cancer Center?
ScholarIQavg h-index
Fred Hutch Cancer Center has an average h-index of 60 in OpenAlex.
What is the ROR of Fred Hutch Cancer Center?
ScholarIQror
The ROR for Fred Hutch Cancer Center is on the source record.
What is the OpenAlex record for Fred Hutch Cancer Center?
ScholarIQopenalex
The OpenAlex for Fred Hutch Cancer Center is on the source record.
Who are the most-cited researchers behind Fred Hutch Cancer Center?
ScholarIQtop researchers by citations
What are the most-cited papers on Fred Hutch Cancer Center?
ScholarIQmost cited works
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
Jonathan E. Rosenberg, Jean Hoffman‐Censits, Tom Powles, Michiel S. van der Heijden, Arjun Vasant Balar, Andrea Necchi, Nancy A. Dawson, Peter H. O’Donnell, Ani Sarkis Balmanoukian, Yohann Loriot, Sandy Srinivas, Margitta Retz, Petros Grivas, Richard W. Joseph, Matthew D. Galsky, Mark T. Fleming, Daniel P. Petrylak, José Luis Perez‐Gracia, Howard A. Burris, Daniel Castellano, Christina Canil, Joaquim Bellmunt, Dean F. Bajorin, Dorothee Nickles, Richard Bourgon, Garrett M. Frampton, Na Cui, Sanjeev Mariathasan, Oyewale O. Abidoye, Gregg Fine, Robert Dreicer
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Julie R. Brahmer, Christina Lacchetti, Bryan J. Schneider, Michael B. Atkins, Kelly Brassil, Jeffrey M. Caterino, Ian Chau, Marc S. Ernstoff, Jennifer M. Gardner, Pamela Ginex, Sigrun Hallmeyer, Jennifer Holter Chakrabarty, Natasha B. Leighl, Jennifer S. Mammen, David F. McDermott, Aung Naing, Loretta J. Nastoupil, Tanyanika Phillips, Laura Porter, Igor Puzanov, Cristina Reichner, Bianca Santomasso, Carole Seigel, Alexander I. Spira, María E. Suarez‐Almazor, Yinghong Wang, Jeffrey S. Weber, Jedd D. Wolchok, John A. Thompson
Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer
Daniel P. Petrylak, Catherine M. Tangen, Maha Hussain, Primo N. Lara, Jeffrey A. Jones, Mary Ellen Taplin, Patrick A. Burch, Donna L. Berry, Carol M. Moinpour, Manish Kohli, Mitchell C. Benson, Eric J. Small, Derek Raghavan, E. David Crawford
Effects of a Combination of Beta Carotene and Vitamin A on Lung Cancer and Cardiovascular Disease
Gilbert S. Omenn, Gary E. Goodman, Mark Thornquist, John R. Balmes, Mark R. Cullen, Andrew G. Glass, James P. Keogh, Frank L. Meyskens, Barbara Valanis, James H. Williams, Scott Barnhart, Samuel P. Hammar
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
Joaquim Bellmunt, Ronald de Wit, David J. Vaughn, Yves Fradet, Jae‐Lyun Lee, Lawrence Fong, Nicholas J. Vogelzang, Miguel Ángel Climent, Daniel P. Petrylak, Toni K. Choueiri, Andrea Necchi, Winald R. Gerritsen, Howard Gurney, David I. Quinn, Stéphane Culine, Cora N. Sternberg, Yabing Mai, Christian Poehlein, Rodolfo F. Perini, Dean F. Bajorin
Who collaborates most closely around Fred Hutch Cancer Center?
ScholarIQco-authorship network
United States
100%
MOST FREQUENT PARTNER INSTITUTIONS
How much of the research on Fred Hutch Cancer Center is open access?
ScholarIQopen access share
75%OPEN ACCESS